A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Completed · Phase 3

Conditions studied: Schizophrenia

In brief

This study evaluated how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.

Key facts

Study ID
NCT05628103
Run by
Otsuka Pharmaceutical Development & Commercialization, Inc.
People needed
101
Starts
2022-12-19
Expected to finish
2024-04-01
Last updated by the study team
2025-12-11

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.